Fractyl Health Inc., a leading metabolic therapeutics company, has announced a partnership with Bariendo Inc., an innovative obesity care platform. The two companies have signed a non-binding Letter of Intent to explore a collaboration centered on Fractyl's investigational procedure, Revita, as a sustainable solution for post-GLP-1 weight maintenance. This partnership aims to address the increasing demand for endoscopic alternatives that offer a holistic approach to maintaining weight loss after GLP-1 drug discontinuation. The collaboration will focus on preparing for the potential integration of Revita into Bariendo's clinical offerings, pending FDA approval, and will include initiatives such as clinical workflow design and provider education.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.